Federal Judge Halts Colorado's Enbrel Price Cap, Exposing State Reform Limits

The ruling pauses enforcement of an upper payment limit set after the board determined Enbrel's list price exceeded affordability thresholds for Colorado residents. The board, established in 2021, reviewed utilization and cost data before selecting the TNF inhibitor as its initial target. Amgen argued the cap would disrupt contracts and supply arrangements, a claim the court found persuasive enough to grant preliminary relief.

This decision underscores structural constraints on state-level pricing tools. Unlike the federal Inflation Reduction Act's Medicare negotiation authority, state boards lack direct purchasing power and must navigate ERISA preemption and commerce clause challenges. Similar boards in Maryland and Washington have advanced slower or narrower actions, revealing uneven implementation across jurisdictions.

Industry litigation strategies now focus on demonstrating irreparable harm rather than contesting affordability findings. The Colorado case may prompt other states to refine selection criteria or seek legislative clarifications before finalizing caps. Federal courts will likely see additional challenges as boards attempt to operationalize limits on biologics with complex rebate structures.

Next steps include potential appeals and parallel proceedings in other states, testing whether administrative price setting can survive scrutiny without federal enabling legislation.